{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:08:17Z","timestamp":1780553297728,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,7,16]],"date-time":"2014-07-16T00:00:00Z","timestamp":1405468800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s00198-014-2796-0","type":"journal-article","created":{"date-parts":[[2014,7,15]],"date-time":"2014-07-15T11:49:46Z","timestamp":1405424986000},"page":"2649-2656","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial"],"prefix":"10.1007","volume":"25","author":[{"given":"N.","family":"Binkley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Bone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"Gilligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. S.","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,16]]},"reference":[{"key":"2796_CR1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1023\/A:1010002907247","volume":"2","author":"CJ Rosen","year":"2001","unstructured":"Rosen CJ (2001) Treatment of postmenopausal osteoporosis: an evidence-based approach. Rev Endocr Metab Disord 2:35\u201343","journal-title":"Rev Endocr Metab Disord"},{"key":"2796_CR2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMcp043801","volume":"353","author":"CJ Rosen","year":"2005","unstructured":"Rosen CJ (2005) Clinical practice. Postmenopausal osteoporosis. N Engl J Med 353:595\u2013603","journal-title":"N Engl J Med"},{"key":"2796_CR3","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1001\/jama.286.22.2815","volume":"286","author":"ES Siris","year":"2001","unstructured":"Siris ES, Miller PD, Barrett-Connor E et al (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286:2815\u20132822","journal-title":"JAMA"},{"issue":"Suppl2","key":"2796_CR4","doi-asserted-by":"crossref","first-page":"S407","DOI":"10.1007\/s00198-010-1253-y","volume":"21","author":"JA Kanis","year":"2010","unstructured":"Kanis JA (2010) Development and use of FRAX in osteoporosis. Osteoporos Int 21(Suppl2):S407\u2013S413","journal-title":"Osteoporos Int"},{"key":"2796_CR5","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s00198-012-1991-0","volume":"23","author":"ES Siris","year":"2012","unstructured":"Siris ES, Boonen S, Mitchell PJ et al (2012) What\u2019s in a name? What constitutes the clinical diagnosis of osteoporosis? Osteoporos Int 23:2093\u20132097","journal-title":"Osteoporos Int"},{"key":"2796_CR6","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00198-014-2655-z","volume":"25","author":"ES Siris","year":"2014","unstructured":"Siris ES, Adler R, Bilezikian J et al (2014) The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int 25:1439\u20131443","journal-title":"Osteoporos Int"},{"key":"2796_CR7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bone.2013.09.008","volume":"57","author":"DK Wysowski","year":"2013","unstructured":"Wysowski DK, Greene P (2013) Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012. Bone 57:423\u2013428","journal-title":"Bone"},{"key":"2796_CR8","doi-asserted-by":"crossref","unstructured":"Solomon DH, Johnston SS, Boytsov NN, et al (2014) Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res Feb 18 (epub)","DOI":"10.1002\/jbmr.2202"},{"key":"2796_CR9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00198-007-0490-1","volume":"19","author":"CH Chesnut 3rd","year":"2008","unstructured":"Chesnut CH 3rd, Azria M, Silverman S et al (2008) Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos Int 19:479\u2013491","journal-title":"Osteoporos Int"},{"key":"2796_CR10","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1073\/pnas.82.15.5064","volume":"82","author":"SD Kittur","year":"1985","unstructured":"Kittur SD, Hoppener JW, Antonarakis SE et al (1985) Linkage map of the short arm of human chromosome 11: location of the genes for catalase, calcitonin, and insulin-like growth factor II. Proc Natl Acad Sci U S A 82:5064\u20135067","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2796_CR11","unstructured":"Nuesch E, Schmidt R (1980) Comparative pharmacokinetics of calitonins. In: Pecile A (ed) Calcitonin 1980. Proc Int Symp Milan; pp 352\u2013364"},{"key":"2796_CR12","unstructured":"Miacalcin\u00ae (calcitonin-salmon) nasal spray package insert (2014) Novartis Pharmaceuticals Corporation, East Hanover, NJ"},{"key":"2796_CR13","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/jbmr.1602","volume":"27","author":"N Binkley","year":"2012","unstructured":"Binkley N, Bolognese M, Sidorowicz-Bialynicka A et al (2012) A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone Miner Res 27:1821\u20131829","journal-title":"J Bone Miner Res"},{"key":"2796_CR14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S8756-3282(02)00791-3","volume":"31","author":"P Qvist","year":"2002","unstructured":"Qvist P, Christgau S, Pederesen BJ et al (2002) Circadian variation in the serum cncentration of C-terminal telopeptide of Type I collagen (Serum CTx): effects of gender, age, menopausal stautus, posture, daylight, serum cortisol, and fasting. Bone 31:57\u201361","journal-title":"Bone"},{"key":"2796_CR15","volume-title":"Clinician\u2019s guide to prevention and treatment of osteoporosis","author":"NOF","year":"2014","unstructured":"NOF (2014) Clinician\u2019s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington"},{"key":"2796_CR16","doi-asserted-by":"crossref","first-page":"356","DOI":"10.7326\/0003-4819-154-5-201103010-00307","volume":"154","author":"U.S. Preventative Services Task Force","year":"2011","unstructured":"U.S. Preventative Services Task Force (2011) Screening for osteoporosis: U.S. Preventative Services Task Force recommnedation statement. Ann Int Med 154:356\u2013364","journal-title":"Ann Int Med"},{"key":"2796_CR17","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1056\/NEJMp1202623","volume":"366","author":"DM Black","year":"2012","unstructured":"Black DM, Bauer DC, Schwartz AV et al (2012) Continuing bisphosphonate treatment for osteoporosis\u2014for whom and for how long? N Engl J Med 366:2051\u20132053","journal-title":"N Engl J Med"},{"key":"2796_CR18","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMp1202619","volume":"366","author":"M Whitaker","year":"2012","unstructured":"Whitaker M, Guo J, Kehoe T et al (2012) Bisphosphonates for osteoporosis\u2014where do we go from here? N Engl J Med 366:2048\u20132051","journal-title":"N Engl J Med"},{"key":"2796_CR19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ijc.21064","volume":"117","author":"CM Ronckers","year":"2005","unstructured":"Ronckers CM, McCarron P, Ron E (2005) Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer 117:281\u2013288","journal-title":"Int J Cancer"},{"key":"2796_CR20","unstructured":"Food and Drug Administration (2013) Background document for meeting of Advisory Committee for reproductive health drugs and drug safety and risk management advisory committee"},{"key":"2796_CR21","unstructured":"Krause D, Hernandez NAS, Vitagliano M et al (2012) One year use of oral recombinant salmon calcitonin is not associated with increased risk of cancer. J Bone Miner Res 27(suppl 1)"},{"key":"2796_CR22","unstructured":"Wells G, Krause D, Chernoff J et al (2013) Does calcitonin-salmon cause cancer? Poster session presented at American Society of Bone and Mineral Research Annual Meeting, Oct 4\u20137, Baltimore MD"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-014-2796-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-014-2796-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-014-2796-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T20:49:13Z","timestamp":1565642953000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-014-2796-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,16]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["2796"],"URL":"https:\/\/doi.org\/10.1007\/s00198-014-2796-0","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,16]]}}}